Article
Biochemical Research Methods
Vilma I. J. Jallinoja, Brandon D. Carney, Meiying Zhu, Kavita Bhatt, Paul J. Yazaki, Jacob L. Houghton
Summary: This study investigates the utilization of antibody-based host-guest chemistry for pretargeted positron emission tomography, aiming to overcome challenges related to in vivo stability and modularity of current pretargeting platforms. The results demonstrate that the novel pretargeting approach utilizing a cucurbit[7]uril host molecule modified antibody and a Ga-68-radiolabeled ferrocene guest radioligand leads to significantly higher tumor uptake compared to nonpretargeted approaches.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Oncology
Santiago Sanchez-Sosa, Carlos Rodriguez-Medina, Ruth Stuckey, Yanira Florido, Guillermo Santana, Jesus Maria Gonzalez Martin, Naylen Cruz-Cruz, Melissa Torres-Ochando, Rosa Fernandez, Nuria Sanchez-Farias, Antonia Cionfrini, Teresa Molero Labarta, Maria Teresa Gomez-Casares, Cristina Bilbao-Sieyro
Summary: Recent advances in sequencing technologies and genomics have led to the development of targeted therapies for personalized treatment of acute myeloid leukemia (AML). However, the molecular profiles of patients who will respond to induction therapy and novel directed therapies are still unknown.
Article
Genetics & Heredity
Parisa Tandel, Reza Ranjbaran, Eqbal Ebrahimi, Alireza Rezvani, Mani Ramzi, Gholamhossein Tamaddon
Summary: This study found that the expression levels of MAP1LC3B, ATG5, ATG10, RB1CC1, and AMBRA1 genes are closely associated with the remission and relapse status of AML patients. The expression levels of these genes can be used to evaluate the remission status and treatment response of AML patients.
MOLECULAR GENETICS & GENOMIC MEDICINE
(2022)
Article
Hematology
Jan-Niklas Eckardt, Christoph Rillig, Klaus Metzeler, Michael Kramer, Sebastian Stasik, Julia-Annabell Georgi, Peter Heisig, Karsten Spiekermann, Utz Krug, Jan Braess, Dennis Girlich, Cristina M. Sauerland, Bernhard Woermann, Tobias Herold, Wolfgang E. Berdel, Wolfgang Hiddemann, Frank Kroschinsky, Johannes Schetelig, Uwe Platzbecker, Carsten Mueller-Tidow, Tim Sauer, Hubert Serve, Claudia Baldus, Kerstin Schaefer-Eckart, Martin Kaufmann, Stefan Krause, Mathias Haenel, Christoph Schliemann, Maher Hanoun, Christian Thiede, Martin Bornhaeuser, Karsten Wendt, Jan Moritz Middeke
Summary: This study used machine learning models to predict complete remission and 2-year overall survival in AML patients, incorporating clinical, laboratory, cytogenetic and molecular genetic data. The predictive features for complete remission included gene mutations such as CEBPA, NPM1, FLT3-ITD, etc., as well as certain clinical indicators. Predictive markers for 2-year overall survival included gene mutations such as CEBPA, FLT3-ITD, white blood cell count, etc.
Article
Hematology
Riccardo Masetti, Edoardo Muratore, Davide Gori, Arcangelo Prete, Franco Locatelli
Summary: The selection of allo-HSCT for pediatric patients with AML in CR1 is still debated. This meta-analysis found that allo-HSCT improved overall survival and disease-free survival compared to chemotherapy in high-risk pediatric AML patients in CR1, but with an increased relapse rate. Sensitivity analysis confirmed the benefit of allo-HSCT on overall survival. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
ANNALS OF HEMATOLOGY
(2022)
Review
Oncology
Kyoko Ito, Keisuke Ito
Summary: Leukemia stem cells play a key role in leukemia initiation and progression, as well as in drug resistance and disease relapse. Eradication of every last leukemia stem cell is crucial for a patient's long-term cure.
Article
Medicine, General & Internal
Sonali P. Barwe, Anne Kisielewski, Ezio Bonvini, John Muth, Jan Davidson-Moncada, Edward Anders Kolb, Anilkumar Gopalakrishnapillai
Summary: CD123 x CD3 dual-affinity retargeting antibody MGD006 shows efficacy in killing pediatric AML cells, and combination treatment with cytarabine does not interfere with MGD006 activity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova
Summary: Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with low-dose cytarabine for the treatment of newly diagnosed older AML patients or those ineligible for intensive chemotherapy. Actinium-lintuzumab (Ac-225-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33 that has shown evidence of single-agent activity in relapsed/refractory AML. Increased expression of MCL-1 is a mediator of resistance to venetoclax in cancer.
Article
Hematology
Oren Pasvolsky, Shai Shimony, Ron Ram, Avichai Shimoni, Liat Shargian, Batia Avni, Ofir Wolach, Tzippy Shochat, Ronit Yerushalmi, Odelia Amit, Pia Raanani, Moshe Yeshurun
Summary: The combination of hypomethylating agents and venetoclax has revolutionized the therapeutic landscape of acute myeloid leukemia (AML), making alloHCT feasible for AML patients achieving first CR with this regimen. Short-term post-transplant outcomes are similar to those expected after traditional intensive chemotherapy.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Iman Abou Dalle, Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour, Zeev Estrov, Courtney D. DiNardo, Naveen Pemmaraju, Alessandra Ferrajoli, Nitin Jain, Sa A. Wang, Nadya Jammal, Gautam Borthakur, Kiran Naqvi, Sarah Pelletier, Sherry Pierce, Michael Andreeff, Guillermo Garcia-Manero, Jorge E. Cortes, Tapan M. Kadia
Summary: The study demonstrates the safety and feasibility of lenalidomide as a maintenance strategy in high-risk AML patients who are not suitable for ASCT, with beneficial effects for patients with negative measurable residual disease. Despite some patients experiencing serious adverse events, lenalidomide is generally well tolerated.
Article
Oncology
Megan Othus, Guillermo Garcia-Manero, John Godwin, James Weick, Derek Stirewalt, Frederick Appelbaum, Harry Erba, Elihu Estey
Summary: In a study of 1247 AML patients over four decades, the decade of therapy was found to be the most important factor affecting long-term survival, while achieving CR within 100 days was the second most important variable. Additionally, the protocol/decade of therapy was identified as a significant predictor of survival at year 2 or 3.
LEUKEMIA & LYMPHOMA
(2021)
Article
Medicine, General & Internal
Lei Wang, Na Lin
Summary: This case report illustrates a patient with chronic lymphocytic leukemia (CLL) who achieved morphological complete remission in both CLL and the subsequent secondary AML after one course of venetoclax monotherapy, demonstrating the potential of targeted therapies in changing the prognosis of hematological malignancies.
Article
Hematology
Wen-Jing Yu, Yu-qian Sun, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Yu Wang
Summary: There is no consensus on whether haploidentical hematological stem cell transplantation (haplo-HSCT) at first complete remission (CR1) stage has prognostic advantages over transplantation at second complete remission (CR2) stage for AML patients. This study compared the outcomes of 768 consecutive AML patients who received haplo-HSCT in CR1 and CR2 groups, and found that in the intermediate-risk subgroup, CR1 group had lower transplant-related mortality (TRM) and superior disease-free survival (DFS) and overall survival (OS) compared to CR2 group.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Maria H. Gilleece, Avichai Shimoni, Myriam Labopin, Stephen Robinson, Dietrich Beelen, Gerard Socie, Ali Unal, Arnold Ganser, Antonin Vitek, Henrik Sengeloev, Ibrahim Yakoub-Agha, Eleni Tholouli, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Summary: This study evaluated the impact of MRD status at the time of HCT on outcomes for AML CR2 patients. It found that being MRD negative, having good-risk cytogenetics, and longer time from diagnosis to HCT were favorable factors for predicting relapse and leukemia-free survival. In-vivo T cell depletion was predictive of relapse.
BLOOD CANCER JOURNAL
(2021)
Article
Biophysics
Takaaki Konuma, Tadakazu Kondo, Masayoshi Masuko, Hiroaki Shimizu, Souichi Shiratori, Takahiro Fukuda, Jun Kato, Masashi Sawa, Yukiyasu Ozawa, Shuichi Ota, Naoyuki Uchida, Yoshinobu Kanda, Shinichi Kako, Shin Fujisawa, Kentaro Fukushima, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: The study found that pretransplant measurable residual disease (MRD) has different prognostic values in core binding factor AML patients, depending on the specific genotype. Effective therapeutic strategies are needed for MRD-positive patients.
BONE MARROW TRANSPLANTATION
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Stig Palm, Tom Back, Sture Lindegren, Ragnar Hultborn, Lars Jacobsson, Per Albertsson
JOURNAL OF NUCLEAR MEDICINE
(2018)
Article
Hematology
Xiaoyu Qu, Hongli Li, Rita M. Braziel, Verena Passerini, Lisa M. Rimsza, Eric D. Hsi, John P. Leonard, Sonali M. Smith, Robert Kridel, Oliver Press, Oliver Weigert, Michael LeBlanc, Jonathan W. Friedberg, Min Fang
Article
Oncology
Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
CLINICAL CANCER RESEARCH
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andreas Hallqvist, Karin Bergmark, Tom Back, Hakan Andersson, Pernilla Dahm-Kahler, Mia Johansson, Sture Lindegren, Holger Jensen, Lars Jacobsson, Ragnar Hultborn, Stig Palm, Per Albertsson
JOURNAL OF NUCLEAR MEDICINE
(2019)
Letter
Hematology
Victor A. Chow, Ajay K. Gopal, David G. Maloney, Cameron J. Turtle, Stephen D. Smith, Chaitra S. Ujjani, Mazyar Shadman, Ryan D. Cassaday, Brian G. Till, Yolanda D. Tseng, Edus H. Warren, Andrei R. Shustov, Manoj P. Menon, Sandra Bhark, Utkarsh H. Acharya, Erin Mullane, Lindsay M. Hannan, Jenna M. Voutsinas, Ted A. Gooley, Ryan C. Lynch
AMERICAN JOURNAL OF HEMATOLOGY
(2019)
Article
Oncology
Haesook T. Kim, Kwang Woo Ahn, Zhen-Huan Hu, Matthew S. Davids, Virginia O. Volpe, Joseph H. Antin, Mohamed L. Sorror, Mazyar Shadman, Oliver Press, Joseph Pidala, William Hogan, Robert Negrin, Steven Devine, Joseph Uberti, Edward Agura, Richard Nash, Jayesh Mehta, Joseph McGuirk, Stephen Forman, Amelia Langston, Sergio A. Giralt, Miguel-Angel Perales, Minoo Battiwalla, Gregory A. Hale, Robert Peter Gale, David I. Marks, Mehdi Hamadani, Sid Ganguly, Ulrike Bacher, Hillard Lazarus, Ran Reshef, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Jean-Yves Cahn, Melhem Solh, Mohamed A. Kharfan-Dabaja, Nilanjan Ghosh, Ayman Saad, Mahmoud Aljurf, Harry C. Schouten, Brian T. Hill, Attaphol Pawarode, Tamila Kindwall-Keller, Nakhle Saba, Edward A. Copelan, Sunita Nathan, Amer Beitinjaneh, Bipin N. Savani, Jan Cerny, Michael R. Grunwald, Jean Yared, Baldeep M. Wirk, Taiga Nishihori, Saurabh Chhabra, Richard F. Olsson, Asad Bashey, Usama Gergis, Uday Popat, Ronald Sobecks, Edwin Alyea, Wael Saber, Jennifer R. Brown
CLINICAL CANCER RESEARCH
(2019)
Article
Medicine, Research & Experimental
Yana Dekempeneer, Tom Back, Emma Aneheim, Holger Jensen, Janik Puttemans, Catarina Xavier, Marleen Keyaerts, Stig Palm, Per Albertsson, Tony Lahoutte, Vicky Caveliers, Sture Lindegren, Matthias D'Huyvetter
MOLECULAR PHARMACEUTICS
(2019)
Article
Oncology
Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted A. Gooley, Darrell R. Fisher, Leona A. Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, Ajay K. Gopal
CLINICAL CANCER RESEARCH
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Calvin N. Leung, Brian S. Canter, Didier Rajon, Tom A. Back, J. Christopher Fritton, Edouard Azzam, Roger W. Howell
JOURNAL OF NUCLEAR MEDICINE
(2020)
Article
Oncology
Sture Lindegren, Per Albertsson, Tom Back, Holger Jensen, Stig Palm, Emma Aneheim
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2020)
Article
Oncology
Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett
CLINICAL CANCER RESEARCH
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tom A. Back, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, Anna M. Wu, Karin Welen
Letter
Hematology
Victor A. Chow, Paul S. Martin, Stephen D. Smith, Brian G. Till, Solomon A. Graf, Kerstin L. Edlefsen, Lindsay M. Hannan, Elahe A. Mostaghel, Ajay K. Gopal
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Hematology
Victor A. Chow, Ajay K. Gopal, Jordan Gauthier, Yolanda D. Tseng, Cameron J. Turtle, David G. Maloney, Mazyar Shadman
Editorial Material
Oncology
Stephen D. Smith, Ajay K. Gopal
JOURNAL OF CLINICAL ONCOLOGY
(2021)